Total pharma M&A deals in January 2019 worth $92.08bn were announced globally, according to GlobalData’s deals database.
The value marked an increase of 1029.4% over the previous month and a rise of 467.4% when compared with the last 12-month average, which stood at $16.23bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $91.24bn. At the country level, the United States topped the list in terms of deal value at $91.23bn.
In terms of volumes, North America emerged as the top region for pharma M&A deals globally, followed by Asia-Pacific and then Europe.
The top country in terms of M&A deals activity in January 2019 was the United States with 28 deals, followed by Germany with five and China with four.
Pharma M&A deals in January 2019: Top deals
The top five pharma M&A deals accounted for 99.4% of the overall value during January 2019.
The combined value of the top five pharma M&A deals stood at $91.56bn, against the overall value of $92.08bn recorded for the month.
The top announced pharma M&A deal tracked by GlobalData in January 2019 was Bristol-Myers Squibb’s $82.83bn acquisition of Celgene.
In second place was Eli Lilly’s acquisition of Loxo Oncology for $8bn and in third place was Taiyo Holdings’ $344.04m asset transaction with Daiichi Sankyo Propharma.
Acrotech Biopharma’s $300m asset transaction with Spectrum Pharmaceuticals and Hitachi Chemical Advanced Therapeutics Solutions’ acquisition of apceth Biopharma for $86.38m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.